Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Fiskus, W, Sharma, S, Shah, B, Portier, B P, Devaraj, S G T, Liu, K, Iyer, S P, Bearss, D, Bhalla, K N·2014·Leukemia

DOI 10.1038/leu.2014.119

Cited by (294)

Items 101–200 of 294

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson · 2020 · Molecules
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development
C T Tsai, Chi Wai Eric So · 2016 · Oncogene
Targeting LSD1 in cancer: Molecular elucidation and recent advances
Wenpeng Cai, Chu Xiao, Tao T. Fan, Ziqin Deng, Di Wang, Yixiao Liu, Chunxiang Li, Jié He · 2024 · Cancer Letters
LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene
Susanna Ambrosio, Stefano Amente, Carmen Daniela Saccà, Mario Capasso, Raffaele Calogero, Luigi Lania, Barbara Majello · 2016 · Oncotarget
ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway
Yan Li, Lei Tao, Zeping Zuo, Yang Zhou, Xinying Qian, Yiyun Lin, Hui Jie, Chunqi Liu, Zhuoling Li, Huaqin Zhang et al. · 2019 · Cancer Letters
Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1
Wei Zhang, Jie Cheng, Pengfei Diao, Dongmiao Wang, Wei Zhang, Hongbing Jiang, Yanling Wang · 2019 · British Journal of Cancer
Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia
Fatemeh Memari, Zeinab Joneidi, Behnaz Taheri, Sedigheh Fekri Aval, Amir Roointan, Nosratollah Zarghami · 2018 · Biomedicine & Pharmacotherapy
Deregulated KLF4 Expression in Myeloid Leukemias Alters Cell Proliferation and Differentiation through MicroRNA and Gene Targets
Valerie Morris, Carrie L. Cummings, Brendan Korb, Sean M. Boaglio, Vivian G. Oehler · 2015 · Molecular and Cellular Biology
Molecular targeting in acute myeloid leukemia
Seah H. Lim, Patrycja M. Dubielecka, Vikram M. Raghunathan · 2017 · Journal of Translational Medicine
Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication
Yoshinori Ishikawa, K. Nakayama, Megumi Morimoto, A Mizutani, Akiko Nakayama, K Toyoshima, A Hayashi, S Takagi, Ryo Dairiki, H Miyashita et al. · 2017 · Oncogenesis
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors
Yue-Yang Ji, Sendong Lin, Yujie Wang, Mingbo Su, Wei Zhang, Hendra Gunosewoyo, Fan Yang, Jia Xuan Li, Jie Tang, Yubo Zhou et al. · 2017 · European Journal of Medicinal Chemistry
Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors
Hong‐Min Liu, Feng‐Zhi Suo, Xiaobo Li, Yinghua You, Chun-tao Lv, Chen-Xing Zheng, Guochen Zhang, Yue-Jiao Liu, Wen-Ting Kang, Yi‐Chao Zheng et al. · 2019 · European Journal of Medicinal Chemistry
Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma
M Naveen Sadhu, Sivanandhan Dhanalakshmi, Chandru Gajendran, Subramanyam Janardhan Tantry, Purushottam M. Dewang, Kannan Murugan, Srinatha Chickamunivenkatappa, Mohd Zainuddin, Sreekala Nair, Krishnakumar Vaithilingam et al. · 2020 · Bioorganic & Medicinal Chemistry Letters
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
Warren C. Fiskus, Christopher Peter Mill, Behnam Nabet, Dimuthu Nuwan Perera, Christine E. Birdwell, Taghi Manshouri, Bernardo H Lara, Tapan Mahendra Kadia, Courtney Denton Dinardo, Koichi Takahashi et al. · 2021 · Blood Cancer Journal
Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy
Ying‐Chao Duan, Wenping Qin, Feng‐Zhi Suo, Xiaoyu Zhai, Yuanyuan Guan, Xiaojuan Wang, Yi‐Chao Zheng, Hong‐Min Liu · 2018 · Bioorganic & Medicinal Chemistry
Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione
Cavan P. Bailey, Mary Figueroa, Achintyan Gangadharan, Dean Anthony Lee, Joya Chandra · 2020 · Frontiers in Immunology
Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia
Amanda Przespolewski, Eunice S. Wang · 2016 · Expert Opinion on Investigational Drugs
Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells
Jianwu Fang, Haiyan Ying, Ting Mao, Yanjia Fang, Yuan Lu, He Wang, Irene Zang, Zhaofu Wang, Ying Lin, Mengxi Zhao et al. · 2017 · Oncotarget
ORY-1001: Overcoming the Differentiation Block in AML
Prithviraj Bose, Marina Y Konopleva · 2018 · Cancer Cell
Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
Abhinav Dhall, Barry M. Zee, Fangxue Yan, Mario Andres Blanco · 2019 · Frontiers in Oncology
Multifunctional epiberberine mediates multi-therapeutic effects
Linqiu Liu, Junjun Li, Yang He · 2020 · Fitoterapia
Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation
Ke Liu, Yanli Liu, Johnathan L. Lau, Jinrong Min · 2015 · Pharmacology & Therapeutics
Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies
Øystein Bruserud, Elise Aasebø, Maria Hernandez-Valladares, Galina Tsykunova, Håkon Reikvam · 2017 · Expert Opinion on Drug Discovery
Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
Iris F. Macheleidt, Priya S. Dalvi, So‐Young Lim, Sonja Meemboor, Lydia Meder, Olivia Käsgen, Marion Müller, Karolin Kleemann, Lingyu Wang, Peter Nürnberg et al. · 2018 · Molecular Oncology
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
Gauri Deb, Bettina Wingelhofer, Fabio M. R. Amaral, Alba Maiqués-Díaz, John A. Chadwick, Gary J. Spencer, Emma L. Williams, Hui Sun Leong, Tamara Maes, Tim C. P. Somervaille · 2019 · Leukemia
Annual review of LSD1/KDM1A inhibitors in 2020
Dong‐Jun Fu, Jun Li, Bin Yu · 2021 · European Journal of Medicinal Chemistry
Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation
Johannes Schulz‐Fincke, Mirjam Hau, Jessica Barth, Dina Robaa, Dominica Willmann, Andreas Kürner, Julian Haas, Gabriele Greve, Tinka Haydn, Simone Fulda et al. · 2017 · European Journal of Medicinal Chemistry
Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy
Ying‐Chao Duan, Shaojie Zhang, Xiaojing Shi, Linfeng Jin, Tong Yu, Yu Song, Yuanyuan Guan · 2021 · European Journal of Medicinal Chemistry
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes
Yoshitaka Sunami, Takashi Yokoyama, Seiko Yoshino, Tomoko Takahara, Yukari Yamazaki, Hironori Harada, Takuro Nakamura · 2021 · Blood Advances
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors
Andrea Milelli, Chiara Marchetti, Eleonora Turrini, Elena Catanzaro, Roberta Mazzone, Daniela Tomaselli, Carmela Fimognari, Vincenzo Tumiatti, Anna Minarini · 2018 · Bioorganic & Medicinal Chemistry Letters
LSD 1 ( KDM 1A)‐independent effects of the LSD 1 inhibitor SP 2509 in cancer cells
Jürgen Sonnemann, Miriam Zimmermann, Christian Marx, Franziska Ebert, Sabine Becker, Marie‐Luise Lauterjung, James F. Beck · 2017 · British Journal of Haematology
Lysine‐specific demethylase‐1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer
Keisuke Kosumi, Yoshifumi Baba, Akihisa Sakamoto, Takatsugu Ishimoto, Kazuto Harada, Kenichi Nakamura, Junji Kurashige, Yukiharu Hiyoshi, Masaaki Iwatsuki, Shiro Iwagami et al. · 2015 · International Journal of Cancer
Histone Deacetylase Inhibitors: Updated Studies in Various Epigenetic-Related Diseases
Clemens Zwergel, Giulia Stazi, Sérgio Valente, Antonello Mai · 2016 · Journal of Clinical Epigenetics
The role and prospect of lysine‐specific demethylases in cancer chemoresistance
Yingqi Song, Guan‐Jun Yang, Dik‐Lung Ma, Wanhe Wang, Chung‐Hang Leung · 2023 · Medicinal Research Reviews
Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
Tarik Möröy, Cyrus Khandanpour · 2019 · Frontiers in Oncology
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers
Gaya Punnia-Moorthy, Peter Hersey, Abdullah Al Emran, Jessamy C. Tiffen · 2021 · Frontiers in Genetics
ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect
Zhaoliang Lu, Yanke Guo, Xiaoya Zhang, Jing Li, Leilei Li, Shuai Zhang, Changliang Shan · 2018 · Frontiers in Pharmacology
LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1
Chunqin Chen, Yanan Wang, Shiyu Wang, Yuan Liu, Jiawen Zhang, Yuyao Xu, Zhenbo Zhang, Wei Bao, Sufang Wu · 2017 · International Journal of Oncology
NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy
Toshiki Etani, Taku Naiki, Aya Naiki‐Ito, Takayoshi Suzuki, Keitaro Iida, Satoshi Nozaki, Hiroyuki Kato, Yuko Nagayasu, Shugo Suzuki, Noriyasu Kawai et al. · 2019 · Journal of Clinical Medicine
LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia
Goichi Tatsumi, Masahiro Kawahara, Ryusuke Yamamoto, Masakatsu Hishizawa, Katsuyuki Kito, Takayoshi Suzuki, Akifumi Takaori‐Kondo, Akira Andoh · 2019 · Leukemia
The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link
Zohar Amsalem, Tasleem Arif, Anna Shteinfer‐Kuzmine, Vered Chalifa Caspi, Varda Shoshan‐Barmatz · 2020 · Cancers
Panobinostat for the treatment of acute myelogenous leukemia
Fortunato Morabito, Maria Teresa Voso, Stefan Hohaus, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lorenzo Iovino, E. Benedetti, Francesco Lo‐Coco, Sara Galimberti · 2016 · Expert Opinion on Investigational Drugs
The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma
Daniel J. García-Domínguez, Lourdes Hontecillas‐Prieto, Pablo Rodríguez‐Núñez, Guillem Pascual‐Pasto, Mònica Vilà-Ubach, Rosa García-Mejías, María José Robles, Òscar M. Tirado, Jaume Mora, Angel Montero Carcaboso et al. · 2018 · Oncotarget
Role of HOXA9 in solid tumors: mechanistic insights and therapeutic potential
Ling Yin Tang, Peng Lin, Chao Tan, Huai Liu, Pan Chen, Hui Zhu Wang · 2022 · Cancer Cell International
Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis
Sun Qunyan, Ding Ding, Xishi Liu, Sun‐Wei Guo · 2016 · Reproductive Biology and Endocrinology
Targeting the GFI1/1B—CoREST Complex in Acute Myeloid Leukemia
Maaike G.J.M. van Bergen, Bert A. van der Reijden · 2019 · Frontiers in Oncology
Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy
Rawan R. Kawaf, Wafaa S.H. Ramadan, Raafat El‐Awady · 2024 · Life Sciences
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation
Liyun Liang, Haiwen Wang, Yongliang Du, Bingling Luo, Ning Meng, Meifeng Cen, Peng Huang, Arasu Ganesan, Shijun Wen · 2020 · Bioorganic Chemistry
Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6
Yuzhi Li, Si Yu, Peiao Yan, Daoyin Gong, Fang-Li Wu, Zhi Xu He, Yuyao Yuan, An-Yan Zhao, Xue Ming TANG, Ruoqi Zhang et al. · 2017 · Oncotarget
Stress-induced phosphoprotein 1 acts as a scaffold protein for glycogen synthase kinase-3 beta-mediated phosphorylation of lysine-specific demethylase 1
Chia-Lung Tsai, An‐Shine Chao, Shih‐Ming Jung, Chiao‐Yun Lin, Angel Chao, Tzu‐Hao Wang · 2018 · Oncogenesis
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia
Steven Goossens, Sofie Peirs, Wouter Van Loocke, Jueqiong Wang, Mina Takawy, Filip Matthijssens, Stefan Sonderegger, Katharina Haigh, Thao Minh Nguyen, Niels Vandamme et al. · 2017 · Blood
Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy
Baohong Wu, Xiangyu Pan, Xuelan Chen, Mei Chen, Kaidou Shi, Jing Xu, Jianan Zheng, Ting Niu, Chong Chen, Xiao Shuai et al. · 2019 · Signal Transduction and Targeted Therapy
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia
Chengyin Min, Nathan Moore, Jeffrey R. Shearstone, Steven N. Quayle, Pengyu Huang, John H. van Duzer, Matthew B. Jarpe, Simon S. Jones, Min Yang · 2017 · PLoS ONE
Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells
Yafei Chu, Zheng Xiao, Nan Jing, Wenjuan Yan, Shanmei Wang, Bing Ma, Jiangfeng Zhang, Yi Li · 2020 · Investigational New Drugs
Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer
Tilak Khanal, Kwangmin Choi, Yuet‐Kin Leung, Jiang Wang, Dasom Kim, Vinothini Govindarajah, Sung‐Gook Cho, Alvaro Puga, Shuk‐Mei Ho, Kyounghyun Kim · 2017 · Scientific Reports
Antiviral Properties of the LSD1 Inhibitor SP-2509
Mitchell R. Harancher, Jessica E. Packard, Shane P. Cowan, Neal A. DeLuca, Jill A. Dembowski · 2020 · Journal of Virology
JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL
Aissa Benyoucef, Katharina Haigh, Andrew R. Cuddihy, Jody J. Haigh · 2022 · Leukemia
Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
Chandru Gajendran, Subramanyam Janardhan Tantry, Naveen Sadhu M, Mohammed Zainuddin, Purushottam M. Dewang, Mahanandeesha Siddappa Hallur, Sreekala Nair, Krishnakumar Vaithilingam, Basavaprabhu Nagayya, Sridharan Rajagopal et al. · 2023 · PLoS ONE
CRISPR screening in hematology research: from bulk to single-cell level
Sarah Meyers, Sofie Demeyer, Jan Cools · 2023 · Journal of Hematology & Oncology
What potential is there for LSD1 inhibitors to reach approval for AML?
Manu Raj Pandey, Eunice S. Wang · 2019 · Expert Opinion on Emerging Drugs
Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications
Feifei Yang, Xue-Li Xu, Ting Hu, Jian‐Quan Liu, Jin-Zhu Zhou, Liying Ma, Hong‐Min Liu · 2023 · Journal of Medicinal Chemistry
Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors
Jiayue Xi, Siyuan Xu, Liming Wu, Tianfang Ma, Rongfeng Liu, Yu‐Chih Liu, Dawei Deng, Yueqing Gu, Jinpei Zhou, Fei Lan et al. · 2017 · Bioorganic Chemistry
Molecular Mechanisms of Apical Periodontitis
Shebli Mehrazarin, Abdullah Alshaikh, Mo Kang · 2016 · Dental Clinics of North America
Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells
Shuang Liu, Wenting Lu, Shouyun Li, Saisai Li, Jia Liu, Yuanyuan Xing, Shuzu Zhang, Joe Z. Zhou, Haiyan Xing, Yingxi Xu et al. · 2017 · Oncotarget
Novel dual‐action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine‐specific histone demethylase 1A inhibitor
Martin Engel, Yi Sing Gee, Dale Cross, Alan T. Maccarone, Benjamin Heng, Amy E. Hulme, Grady C. Smith, Gilles J. Guillemin, Brett William Stringer, Christopher J. T. Hyland et al. · 2018 · Journal of Neurochemistry
Lysine-specific demethylase 1 inhibition enhances autophagy and attenuates early-stage post-spinal cord injury apoptosis
Yang Gu, Dehui Chen, Linquan Zhou, Xin Zhao, Jiemin Lin, Bin Lin, Taotao Lin, Zhi Chen, Zhaohong Chen, Zhenyu Wang et al. · 2021 · Cell Death Discovery
Iron-(Fe3+)-Dependent Reactivation of Telomerase Drives Colorectal Cancers
Raghuvaran Shanmugam, Prativa Majee, Wei Shi, Mert B. Ozturk, Thamil Selvan Vaiyapuri, Khaireen Idzham, Anandhkumar Raju, Seung Hee Shin, Kerem Fidan, Joo-Leng Low et al. · 2024 · Cancer Discovery
Epigenetic regulation of LSD1 during mammary carcinogenesis
Yadi Wu, Binhua Peter Zhou · 2014 · Molecular & Cellular Oncology
Loss of MEN1 leads to renal fibrosis and decreases HGF‐Adamts5 pathway activity via an epigenetic mechanism
Bangming Jin, Jiamei Zhu, Yüxia Zhou, Li Liang, Yunqiao Yang, Lifen Xu, Tuo Zhang, Po Li, Ting Shuang Pan, Bing Guo et al. · 2022 · Clinical and Translational Medicine
Drug Design Concepts for LSD1‐Selective Inhibitors
Yosuke Ota, Takayoshi Suzuki · 2018 · The Chemical Record
The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
Jianlin Wang, Qian Yu, Zhaoping Qiu, Tao Dai, Shuxia Wang, Xiuwei H. Yang, Bernard Mark Evers, Yadi Wu · 2020 · Aging
Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors
Ying‐Chao Duan, Tong Yu, Linfeng Jin, Shaojie Zhang, Xiaojing Shi, Yizhe Zhang, Nanqian Zhou, Yongtao Xu, Wenfeng Lu, Huimin Zhou et al. · 2023 · European Journal of Medicinal Chemistry
Leveraging non-enzymatic functions of LSD1 for novel therapeutics
Yihui Song, Bin Yu · 2025 · Trends in Pharmacological Sciences
Advances on Epigenetic Drugs for Pediatric Brain Tumors
Panagiotis Skouras, Mariam Markouli, Dimitrios Strepkos, Christina Piperi · 2022 · Current Neuropharmacology
Histone deacetylase inhibitors for the treatment of cancer stem cells
Marcela Dvořáková, Tomáš Vaněk · 2016 · MedChemComm
Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia
Jens Przybilla, Lydia Hopp, Michael Lübbert, Markus Loeffler, Joerg Galle · 2017 · Epigenetics
Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors
Cristina Mascaró, Alberto Ortega, Elena Carceller, Raquel Ruiz Rodriguez, Filippo Ciceri, Serena Lunardi, Yu Li, Manuel Hilbert, Tamara Maes · 2019 · Journal of Biological Chemistry
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
Clara Alcon, Fernando Martín, Estela Prada, Jaume Mora, Aroa Soriano, Gabriela Guillén, Soledad Gallego, Josep M Roma, Josep Samitier, Alberto Villanueva et al. · 2022 · Cell Death Discovery
LSD1 inhibition modulates transcription factor networks in myeloid malignancies
Emily E. Hartung, Kanwaldeep Singh, Tobias Berg · 2023 · Frontiers in Oncology
Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer
Mei-Ling Le, Wenhua Lu, Xiaozhuo Tan, Bingling Luo, Tiantian Yu, Yameng Sun, Zhirong Guo, Peng Huang, Daqian Zhu, Qiang Wu et al. · 2024 · Journal of Medicinal Chemistry
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells
Alexandra Sachkova, Swetlana Sperling, Dorothée Mielke, Bawarjan Schatlo, Veit Rohde, Milena Ninković · 2018 · Anticancer Research
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling
Huiyan Zhen, Xinxin Zhang, Lei Zhang, Ming‐Ming Zhou, Liangliang Lu, Lihong Wu, Na He, Juan Wang, Rui Li, Yan Guo · 2021 · Acta Biochimica et Biophysica Sinica
Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment
Deping Li, Hailiu Liang, Yifei Wei, Hao Xiao, Xiaopeng Peng, Wanyi Pan · 2023 · European Journal of Medicinal Chemistry
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
Michael W.M. Kühn, Naveen Pemmaraju, Florian Heinrich Heidel · 2025 · Leukemia
Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1
Xiangyu Zhang, Yixiang Sun, Ziheng Zhang, Hanxun Wang, Jian Wang, Dongmei Zhao · 2021 · Biochimica et Biophysica Acta (BBA) - General Subjects
The Histone Lysine-specific Demethylase 1 Inhibitor, SP2509 Exerts Cytotoxic Effects against Renal Cancer Cells through Downregulation of Bcl-2 and Mcl-1
Kaixin Wu, Seon Min Woo, Taeg Kyu Kwon · 2020 · Journal of Cancer Prevention
Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis
Ornela Sulejmani, Laura Grunewald, Lena Andersch, Silke Schwiebert, Anika Klaus, Annika Winkler, Kathy Astrahantseff, Angelika Eggert, Anton George Henssen, Johannes Hubertus Schulte et al. · 2021 · Cancers
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
Lin Xiao, Mawar Karsa, Emma Ronca, Angelika Bongers, Angelika Kosciolek, Ali El‐Ayoubi, Jezrael L. Revalde, Janith A. Seneviratne, Belamy B. Cheung, Laurence C. Cheung et al. · 2022 · Frontiers in Oncology
The scaffolding function of LSD1/KDM1A reinforces a negative feedback loop to repress stem cell gene expression during primitive hematopoiesis
Mattie J. Casey, Alexandra M. Call, Annika V. Thorpe, Cicely A. Jette, Michael E. Engel, Rodney A. Stewart · 2022 · iScience
KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma
Qingyuan Yang, Shiyin Wei, Cen Qiu, Chenjie Han, Zunguo Du, Ning Wu · 2024 · Cell Death and Disease
Histone demethylases in autophagy and inflammation
Yaoyao Ma, Wenting Lv, Yi Chen Guo, Tong Yin, Yujie Bai, Ziqi Liu, Chao Chen, WenjuanYang, Jiayi Feng, Wenbin Qian et al. · 2025 · Cell Communication and Signaling
SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling
Alan Jiang, Weiqi Wu, Caixia Xu, Longbing Mao, Sha Ao, Huifeng Guo, Xiantao Sun, Jing Tao, Yi Sang, Guofu Huang · 2022 · Investigative Ophthalmology & Visual Science
c-Mpl-del, a c-Mpl alternative splicing isoform, promotes AMKL progression and chemoresistance
Fei Li, Yuanyan Xiong, Mo Yang, Peiling Chen, Jingkai Zhang, Qiong Wang, Miao Xu, Yiming Wang, Zuyong He, Xin Zhao et al. · 2022 · Cell Death and Disease
Phosphoproteomic analysis on ovarian follicles reveals the involvement of LSD1 phosphorylation in Chicken follicle selection
Yanhong Zhang, Qiuyue Chen, Yuanyuan Guo, Li Kang, Yi Sun, Yunliang Jiang · 2023 · BMC Genomics
The Role of Chromatin-Associated Proteins in Cancer
Kristian Helin, Saverio Minucci · 2016 · Annual Review of Cancer Biology
Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance
Clement Agboyibor, Jianshu Dong, Clement Yaw Effah, Emmanuel Kwateng Drokow, Maxwell Ampomah‐Wireko, Waqar Pervaiz, Augustina Sangmor, Xinli Ma, Jian Li, Hong‐Min Liu et al. · 2022 · Biomedicine & Pharmacotherapy
Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases
Fei Mao, Yujiang Geno Shi · 2023 · Advances in experimental medicine and biology
Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study
Jessica D. Johnson, Salvador Alejo, Sridharan Jayamohan, Gangadhara R. Sareddy · 2023 · Expert Opinion on Therapeutic Targets
Pharmacoepigenetics of LSD1 Inhibitors in Cancer
Bin Yu, Hong‐Min Liu · 2019 · Elsevier eBooks
Epigenetic drugs for cancer therapy
Bowen Yan, Xuehui Li, Alta Johnson, Yurong Yang, Wei Jian, Yi Qiu · 2015 · Elsevier eBooks